All News
ACR21 Best Abstracts - Day 1
The RheumNow faculty have been glued to their monitors all day, watching video, and running down abstract presentations to find the best – several of these stood out as #ACRBests. Here is a listing of “Best” they saw on Day 1.
Read Article
Work participation in patients with axial spondyloarthritis
Patients with axial spondyloarthritis (axSpA) often have increased absence from work as well as reduced productivity at work, which can have profound impacts for not only the affected individual and their families, but also lead to wider economic and social burden.
Read Article
Although baseline dz was similar in axSpA males/females, study found male pts had more improvements in ASDAS-CRP, CRP, and PGA than females in 6 years of follow-up. Abs 0620 #ACR21 #RheumNow @RheumNow https://t.co/Qr657YeniA https://t.co/35t4oIUSmS
Dr. Rachel Tate uptoTate ( View Tweet)
An ongoing axSpA cohort in Netherlands study assessed the rate of progression of nr-axSpA to AS patients over a 6 y period
Every 2 y approximately 10% of patients progressed from nr-axSpA to AS
Abst # 0907 #ACR21 @RheumNow https://t.co/gGhhssLS5N
swethaann23 swethaann23 ( View Tweet)
Getting closer to personalised medicine in AS, ECM-mediated biomarkers may help predict response to Adalimumab in AS. The biomarkers C1M, C6M and
PRO-C4 were lower in responders to adalimumab treatment after 24 weeks @RheumNow #ACR21 Abst#0915 https://t.co/K2YxPvUAwu https://t.co/w9kcBSFeG9
Dr. Antoni Chan synovialjoints ( View Tweet)
Interesting study. 79 nr-axSpA pts observed for 6 years. Every 2 yrs approximately 10% of pts progressed from nr-axSpA to AS! Next step: evaluate dz characteristics and determine potential at risk pts. Abs 0907 #ACR21 #RheumNow @RheumNow https://t.co/aRjXWjkVKg https://t.co/BiHFgDR8Kv
Dr. Rachel Tate uptoTate ( View Tweet)
Abst0898 #ACR21 @RheumNow MRI findings of Vertebral Corner Inflammation & Vertebral Corner Fat Deposition associated w/syndesmophyte formation 2 y later, ORs 1.87-2.58 for various VCI/VCFD patterns. Protection against syndesmophyte seen if both VCI and VCFD were absent (OR 0.35) https://t.co/t01nxdEwON
Olga Petryna DrPetryna ( View Tweet)
There is increase in ASDAS, BASDAI, CRP and faecal calprotectin levels although not reaching a clinical flare in AS patients who had CZP stopped compared to those who continue CZP full or reduced dose @RheumNow #ACR21 Abst#0916 https://t.co/Wlwirs1QXF https://t.co/jE4smHMXBI
Dr. Antoni Chan synovialjoints ( View Tweet)
In support of early dx and tx in AS! Study of AS pts treated with GLM: those w/ early dz showed sign/symptom improvement compared to those w/ late dz. IV GLM better overall regardless of dz duration. Abs 0912 #ACR21 #RheumNow @RheumNow https://t.co/S2L97c7oQO https://t.co/XXpveRwwmQ
Dr. Rachel Tate uptoTate ( View Tweet)
Abst0919 #ACR21 @RheumNow Phase III COAST-V 52W (PBO)-controlled study examined the efficacy of IXE in pts with active AS. SF-36 bodily pain, improvements were observed at W16 & W52 whether inflammation was controlled or not per MRI, CRP, MRI+CRP, or BASDAI 5/6. https://t.co/uHLwFctzPr
Olga Petryna DrPetryna ( View Tweet)
2 year extension study on Upadacitinib in active AS
⭐️ASAS40 response maintained
⭐️MRI SPARCC scores decreased and maintained
⭐️infections most common AE
⭐️NO MACE, lymphoma, skin cancer, GI perforations
Abs#924
#ACR21 #ACRBest
@RheumNow
https://t.co/725IRAOgtW https://t.co/FVUoCi6aoQ
Robert B Chao, MD doctorRBC ( View Tweet)
No significant difference in effectiveness/treatment survival of different TNFi in axSpA
Failure of 1st TNFi did not diminish effectiveness of a second TNFi
Abs#938
#ACR21 @RheumNow
https://t.co/SLrOV7wmvU https://t.co/fkpmseVwF6
Robert B Chao, MD doctorRBC ( View Tweet)
Abst 0947 #ACR21 @RheumNow KikGR x TNFDARE/+ mice study assessed contribution of gut-derived T cells to increased joint inflammation through production of pro-inflammatory cytokines like IL-17 and TNF. Photolabeled gut-trafficked T cells are observed in the Achilles enthesis
Olga Petryna DrPetryna ( View Tweet)
No evidence to show increased risk of incident hypertension w/ TNFi use, after accounting for baseline & time-dependent confounding factors, in prospective AS cohort. Abs 0910 #ACR21 #RheumNow @RheumNow https://t.co/1SpQ51ftlK
Dr. Rachel Tate uptoTate ( View Tweet)
French, real-world axSpA cohort analysis shows SEC and TNFi retention rates similar. What do you see in your practice? Abs 0911 #ACR21 #RheumNow @RheumNow https://t.co/vu3zUwfktl https://t.co/v6DLjWJMn4
Dr. Rachel Tate uptoTate ( View Tweet)
@rheum_cat presenting a really well designed study looking at association between TNFi use and incident hypertension in axSpA. No association found. Abstr#0910 #ACR21 @RheumNow https://t.co/w7o1oDreVL
Richard Conway RichardPAConway ( View Tweet)
Abst0569 #acr21 @RheumNow mortality in SpA:⬆️ overall mortality in AS (RR 1.64, 95% CI: 1.49-1.80,) but not PsA (RR: 1.12, 95% CI: 0.96-1.30). CV, resp & infection specific mortality significantly higher for PsA Cancer related mortality in PsA not higher than the gen pop
Olga Petryna DrPetryna ( View Tweet)
Abst 0562
Ungprasert & colleagues examine hospitalization and resource utilization among patients with #AnkylosingSpondylitis
- Prevalence is high
- Infection was among the most common reasons for hospitalization (sepsis, pneumonia, UTI)
#ACR21 @RheumNow https://t.co/UftoFllE1v
Akhil Sood MD AkhilSoodMD ( View Tweet)
Abst0907 #ACR21 @RheumNow observation of GLAS cohort of nrAxSpA pts over 6 yrs showed ~10% of pts progress to AS every 2 years. Specifically after two, four and six years, 8/79 (10.1%), 4/48 (8.3%) and 3/24 (12.5%) nr-axSpA patients progressed to AS. https://t.co/hVpNz1kEgE
Olga Petryna DrPetryna ( View Tweet)
